Form 4: Alto Neuroscience Director Acquires Stock Options

Ramiro Sanchez, a Director at Alto Neuroscience, Inc., acquired 10,958 stock options with an exercise price of $24.63.

Summary

• Ramiro Sanchez, a Director at Alto Neuroscience, Inc., was granted 10,958 stock options on May 12, 2026.
• The options have an exercise price of $24.63 per share.
• These options are part of the Issuer's Non-Employee Director Compensation Policy.
• The underlying shares vest on the earlier of the one-year anniversary of the grant date or the Issuer's next Annual Meeting, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard director compensation rather than a significant financial event or strategic shift.

Positives

• Director compensation through stock options aligns management incentives with shareholder value.
• The grant of options suggests confidence in the company's future performance and stock price appreciation.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The exercise price of $24.63 indicates an expectation of future stock price appreciation; if the stock price does not exceed this, the options may not be valuable.
• The options represent potential future dilution for existing shareholders.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Alto Neuroscience, Inc.
• If the company fails to meet performance expectations, the options may expire worthless.
• Changes in market conditions or regulatory environments could negatively impact the company's stock price and the value of the options.

Future Outlook

The vesting schedule and exercise price of the stock options suggest an expectation of future stock price appreciation for Alto Neuroscience, Inc.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company growth and shareholder returns.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Director Ramiro Sanchez is a related party transaction, as it is part of the company's compensation policy for non-employee directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also alignment of director incentives with shareholder value.
• Employees: Standard compensation practice, no direct immediate impact.
• Management: Reinforces the incentive structure for directors.

Next Steps

• The stock options will vest according to the schedule outlined, contingent on the reporting person's continuous service.
• The reporting person may exercise the vested options at the price of $24.63 per share until the expiration date of May 11, 2036.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Securities Exchange Act